Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 7

Results: 9

Association Between Migraine and Ischemic Cardio-Cerebrovascular Disease (CCVD) and Effects of Triptans and Ergotamine on the Risk of Ischemic CCVD in Patients with Migraine in the Korean NHIS-HEALS Cohort.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 541, doi. 10.1007/s40261-023-01290-7

By:

Kim, Yonghwan;
Shin, Sang-Jun;
Lee, Jae-woo;
Kim, Ye-Seul;
You, Hyo-Sun;
Kim, Joungyoun;
Kang, Hee-Taik

Publication type:

Article

Efficacy and Safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Pedis: A Phase III Randomised, Double-Blind, Parallel-Group, Active-Controlled Study in Indian Adult Patients.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 565, doi. 10.1007/s40261-023-01288-1

By:

Sinha, Shubhadeep D.;
Rajamma, Avula;
Bandi, Mohan Reddy;
Sriramadasu, Sreenivasa Chary;
Sahu, Suvash;
Kothiwala, Raj Kumar;
Halder, Saswati;
Sankerneni, Abhilash;
Panapakam, Muralidhar;
Vemireddy, Venkata Narayana Reddy;
Vattipalli, Ramya;
Devireddy, Srinivas Reddy

Publication type:

Article

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 551, doi. 10.1007/s40261-023-01286-3

By:

Brown, Mark T.;
Cornblath, David R.;
Koltzenburg, Martin;
Gorson, Kenneth C.;
Hickman, Anne;
Pixton, Glenn C.;
Gaitonde, Puneet;
Viktrup, Lars;
West, Christine R.

Publication type:

Article

Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 475, doi. 10.1007/s40261-023-01289-0

By:

Karsten Dafonte, Katharina;
Weber, Lisa;
Chmielewski, Florian;
Böhmer, Anna Maria;
Lutz, Philipp;
Hartmann, Gunther;
Jaehde, Ulrich;
Coenen, Martin

Publication type:

Article

Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 575, doi. 10.1007/s40261-023-01287-2

By:

van Broekhoven, Amber;
Eikelboom, John W.;
Nidorf, Stefan M.;
Mosterd, Arend;
Cornel, Jan H.

Publication type:

Article

Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 463, doi. 10.1007/s40261-023-01283-6

By:

Nam, Kyungae;
Cho, Daniel Sung-Ho;
Kim, Hyunji;
Kwon, Byungjin;
Yoon, Yebin;
Park, Chanhyun;
Kim, Eui-Soon;
Youn, Jong-Chan;
Park, Sun-Kyeong

Publication type:

Article

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 517, doi. 10.1007/s40261-023-01280-9

By:

Herranz-Pinto, Pedro;
Alonso-Pacheco, Maria Luisa;
Feltes-Ochoa, Rosa;
Mayor-Ibarguren, Ander;
Servera-Negre, Guillermo;
Busto-Leis, Jose Manuel;
Gonzalez-Fernández, Maria Angeles;
Herrero-Ambrosio, Alicia

Publication type:

Article

Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 529, doi. 10.1007/s40261-023-01279-2

By:

Justo, Nahila;
Wilking, Nils;
Jönsson, Linus

Publication type:

Article

Safety and Pharmacokinetics of PSD502 in Healthy Chinese Male and Female Volunteers: Two Randomized, Double-Blind, Placebo-Controlled, Phase I Trials.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 7, p. 503, doi. 10.1007/s40261-023-01277-4

By:

Wang, Fangfang;
Liu, Zhiping;
Niu, Xiaoye;
Zhao, Lin;
Zhu, Jixiang;
Qi, Linjing;
Liu, Lu;
Liu, Ziyang;
Sun, Yunan;
Diao, Lei;
Lu, Jun;
Zhou, Yongchun;
Wang, Xiaoye;
Li, Haiyan

Publication type:

Article